The U.S. and Europe have shifted their focus toward booster doses, which have been proven critical in protection against new strains. Learn the latest developments in this Trendline.
The world is still grappling with how to stay ahead of a mutating coronavirus. The vaccine focus has now shifted to sustaining longer-term efforts, and developers like Pfizer and Moderna have successfully updated their vaccines to better match circulating omicron variants.
Included in this Trendline:
Pfizer, BioNTech data support new Covid booster’s advantage over original vaccine
Novavax details trial results for omicron-targeting booster shots
Moderna cuts sales forecasts for its COVID-19 vaccine